On Mon­day, we held our fourth an­nu­al #JPM event — and the team hit a key mile­stone that I’d like to share with the en­tire End­points News au­di­ence: We live-streamed the con­ver­sa­tion and had near­ly triple the num­ber of ex­ec­u­tives watch­ing on­line than we had in the sold-out crowd of 320.

For a me­dia com­pa­ny on a mis­sion to con­nect the bio­phar­ma world in big­ger and bet­ter ways, we’re proud of how we were able to ex­tend the reach of our fran­chise event. Paid sub­scribers were giv­en ac­cess to the stream in re­al time, and now, two days lat­er, we’re open­ing it up to every­one in this post.

John Car­roll, my part­ner at End­points, con­duct­ed a marathon 3-hour ses­sion that in­clud­ed two pan­el dis­cus­sions and a fire­side chat with some of the in­dus­try’s biggest news­mak­ers.

The art of the biotech deal was our first pan­el, and it fea­tured Mar­i­anne De Backer (Bay­er), Arie Bellde­grun (Al­lo­gene Ther­a­peu­tics), Stéphane Ban­cel (Mod­er­na Ther­a­peu­tics), Vivek Ra­maswamy (Roivant Sci­ences), and Josh Bilenker (Loxo On­col­o­gy by Eli Lil­ly).

Next, John Chimin­s­ki, the CEO of Catal­ent, and John Car­roll had a fas­ci­nat­ing one-on-one chat that touched on some of the most crit­i­cal is­sues in man­u­fac­tur­ing gene ther­a­pies and next-gen bi­o­log­ics.

Last­ly, we have Talk­ing Points on Pric­ing, an is­sue that con­tin­ues to dom­i­nate, and this pan­el did not dis­ap­point with PhRMA’s Steve Ubl, Na­tion­al MS So­ci­ety’s Bari Tal­ente, ICER’s Steve Pear­son, and blue­bird’s Nick Leschly all bring­ing their sharp per­spec­tives to the End­points News au­di­ence.

It was a fan­tas­tic event and we hope you en­joy the show. We have a full slate of events this year in San Diego, Boston, Lon­don, and more and hope to catch you there in per­son (or on­line!).

Pho­tog­ra­phy by Jeff Ru­mans, End­points News. Livestream by Spark Dig­i­tal.

The mRNA player Moderna is further cementing its presence on the African continent.

Moderna announced on Thursday that it has finalized an agreement with Kenya’s government to partner up and bring an mRNA manufacturing facility to the east African nation. The new facility aims to manufacture up to 500 million doses of vaccines annually. Moderna also said the new facility will have the ability to spike its production capabilities to respond to public health emergencies on the continent or globally.

Paul McKenzie took over as CEO of Australian pharma giant CSL this month, following in the footsteps of long-time CSL vet Paul Perreault.

With an eye on mRNA, and quickly commercializing its new, $3.5 million-per-shot gene therapy for hemophilia B, McKenzie and chief medical officer Bill Mezzanotte answered some questions from Endpoints News this afternoon about where McKenzie is going to take the company and what advances may be coming to market from CSL’s pipeline. Below is a lightly edited transcript.

Boehringer Ingelheim reported human pharma sales of €18.5 billion on Wednesday, led by type 2 diabetes and heart failure drug Jardiance and pulmonary fibrosis med Ofev. Jardiance sales reached €5.8 billion, growing 39% year over year, while Ofev took in €3.2 billion, notching its own 20.6% annual jump.

However, Boehringer is also looking ahead with its pipeline, estimating “In the next seven years the company expects about 20 regulatory approvals in human pharma.”